Table 1.
Peak integrals relative to those of creatine (mean ± standard deviation) in the parietal white and grey matter of patients with acute-on-chronic liver failure, acute liver failure, and chronic liver disease compared with healthy controls. (Verma et al. 2007).
| Metabolites |
||||
|---|---|---|---|---|
| Study | NAA/Cr | Cho/Cr | Glx/Cr | mI/Cr |
| A. Controls (n = 10) | 1.25 ± 0.20 | 0.25 ± 0.03 | 2.14 ± 0.42 | 0.58 ± 0.15 |
| B. ACLF patients (n = 9) | 0.84 ± 0.28 | 0.17 ± 0.04 | 3.07 ± 0.72 | 0.35 ± 0.16 |
| C. ALF patients (n = 10) | 1.14 ± 0.15 | 0.17 ± 0.08 | 4.39 ± 1.25 | 0.55 ± 0.11 |
| D. CLD patients (n = 10) | 0.97 ± 0.21 | 0.20 ± 0.06 | 3.15 ± 0.69 | 0.25 ± 0.17 |
| Mann-Whitney test (P value) | ||||
| A vs. B | <0.001 | <0.001 | 0.029 | 0.009 |
| A vs. C | 0.282 | 0.002 | <0.001 | 0.314 |
| A vs. D | 0.004 | 0.043 | <0.001 | 0.002 |
| B vs. C | <0.001 | 0.705 | 0.002 | 0.001 |
| B vs. D | 0.035 | 0.105 | 0.436 | 0.105 |
| C vs. D | 0.036 | 0.223 | 0.008 | 0.001 |
| One-way ANOVA (P value) | <0.001 | 0.004 | <0.001 | <0.001 |
ACLF, acute-on-chronic liver failure; ALF, acute liver failure; ANOVA, analysis of variance; Cho, choline; CLD, chronic liver disease; Cr, creatine; Glx, glutamine/glutamate; mI, myoinositol; NAA, N-acetylaspartate.